Kidney Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: KDN017 MIFTS: 59	Kidney Cancer Categories: Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer ¹² ⁴⁴ ¹⁵

Renal Cancer ¹² ⁷⁷ ³⁰ ⁵⁶ ¹⁵

Renal Carcinoma ¹⁷ ⁷⁴

Kidney Neoplasm ¹⁷ ⁷⁴

Malignant Neoplasm of Kidney Except Pelvis ¹²

Malignant Neoplasm of Kidney ⁷⁴

Malignant Tumour of Kidney ¹²

Renal Cell Carcinoma ⁷⁴

Kidney Carcinoma ⁶

Kidney Neoplasms ⁴⁵

Cancer, Kidney ⁴¹

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases Genetic diseases
Anatomical: Nephrological diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of urinary tract

Malignant neoplasm of kidney, except renal pelvis

External Ids:

Disease Ontology ¹² DOID:263

ICD9CM ³⁶ 189.0

MeSH ⁴⁵ D007680

NCIt ⁵¹ C120456 C3150 C7548

SNOMED-CT ⁶⁹ 93849006

ICD10 ³⁴ C64

EFO ¹⁷ EFO_0002890 EFO_0003865

UMLS ⁷⁴ C0007134 C0022665 C0494158 more

Sources

Summaries for Kidney Cancer

MedlinePlus : ⁴⁴ You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is MTOR (Mechanistic Target Of Rapamycin Kinase), and among its related pathways/superpathways are MicroRNAs in cancer and LncRNA-mediated mechanisms of therapeutic resistance. The drugs Avastin and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and bone.

Disease Ontology : ¹² A urinary system cancer that is located in the kidney.

Wikipedia : ⁷⁷ Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Sources

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ

Renal Carcinoma, Familial

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 282)

#	Related Disease	Score	Top Affiliating Genes
1	renal cell carcinoma, nonpapillary	32.4	GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MET
2	clear cell renal cell carcinoma	30.2	MALAT1 MEG3 MET MIR21 MTOR PVT1
3	melanoma	30.2	GAS5 H19 HOTAIR MALAT1 MEG3 MIR15A
4	gallbladder cancer	29.9	H19 HOTAIR MALAT1 MEG3
5	leukemia, acute myeloid	29.9	HOTAIR MALAT1 MEG3 MIR21 MTOR
6	liver cirrhosis	29.9	GAS5 HOTAIR MALAT1 MEG3
7	small cell cancer of the lung	29.8	HOTAIR MALAT1 MIR21
8	thyroid cancer	29.8	GAS5 H19 HOTAIR MALAT1 MET PVT1
9	bladder cancer	29.8	GAS5 H19 HIF1A-AS2 HOTAIR MALAT1 MEG3
10	pituitary adenoma	29.8	H19 HOTAIR MALAT1 MEG3 MIR15A
11	myeloma, multiple	29.7	GAS5 H19 HOTAIR MALAT1 MEG3 MIR15A
12	esophageal cancer	29.5	GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
13	ovarian cancer	29.4	GAS5 H19 HOTAIR MALAT1 MEG3 MIR150
14	pancreatic cancer	29.3	GAS5 H19 HOTAIR MALAT1 MEG3 MET
15	colorectal cancer	29.2	GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1 MALAT1
16	gastric cancer	29.1	GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1 MALAT1
17	prostate cancer	29.1	GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
18	hepatocellular carcinoma	29.0	GAS5 H19 HOTAIR KCNQ1OT1 MALAT1 MEG3
19	breast cancer	28.9	EPB41L4A-DT GAS5 H19 HIF1A-AS2 HOTAIR KCNQ1OT1
20	lung cancer	28.8	EPB41L4A-DT GAS5 H19 HIF1A-AS1 HOTAIR KCNQ1OT1
21	childhood multilocular cystic kidney neoplasm	12.1
22	kidney cancer, childhood	12.1
23	kidney carcinoma in situ	12.0
24	renal carcinoma, familial	12.0
25	hereditary leiomyomatosis and renal cell cancer	11.4
26	birt-hogg-dube syndrome	11.3
27	oncocytoma	11.3
28	renal cell carcinoma, xp11-associated	11.3
29	kidney rhabdoid cancer	11.2
30	von hippel-lindau syndrome	11.2
31	renal cell carcinoma, papillary, 1	11.2
32	chromophobe renal cell carcinoma	11.1
33	collecting duct carcinoma	11.1
34	kidney benign neoplasm	11.0
35	familial renal papillary carcinoma	11.0
36	wilms tumor 5	11.0
37	mucinous tubular and spindle renal cell carcinoma	11.0
38	rhabdoid cancer	10.9
39	congenital mesoblastic nephroma	10.9
40	hereditary paraganglioma-pheochromocytoma syndromes	10.9
41	beckwith-wiedemann syndrome	10.8
42	wilms tumor 1	10.8
43	denys-drash syndrome	10.8
44	perlman syndrome	10.8
45	kidney hemangiopericytoma	10.8
46	transitional cell carcinoma	10.8
47	kidney sarcoma	10.8
48	kidney clear cell sarcoma	10.8
49	simpson-golabi-behmel syndrome	10.8
50	functionless pituitary adenoma	10.5	HOTAIR MEG3

Graphical network of the top 20 diseases related to Kidney Cancer:

Sources

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:

flank pain

Sources

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁹	Company	Approval Date
1	Avastin ¹⁹ ⁵⁰	BEVACIZUMAB	Genentech	July 2009
FDA Label: Avastin Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer Indications and Usage: ¹⁹ Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1) DrugBank Targets: ¹⁶ 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c Mechanism of Action: ¹⁹ Target: VEGF Action: inhibitor FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
2	Nexavar ¹⁹ ⁵⁰	SORAFENIB TOSYLATE	Bayer/Onyx	December 2005
FDA Label: Nexavar Disease/s that Drug Treats:Renal Cell Carcinoma Indications and Usage: ¹⁹ NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3) DrugBank Targets: ¹⁶ 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1 Mechanism of Action: ¹⁹ Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-Ã Action: inhibitor FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-Ã). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.
3	Proleukin ¹⁹ ⁵⁰	ALDESLEUKIN	Chiron	January 1998
FDA Label: Proleukin Disease/s that Drug Treats:Metastatic melanoma Indications and Usage: ¹⁹ ProleukinÂ® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. SeeâCONTRAINDICATIONSâ, âWARNINGSâ and âPRECAUTIONSâ sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See âCLINICAL PHARMACOLOGYâ section,âCLINICAL STUDIESâ section and âADVERSE REACTIONSâ section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited. DrugBank Targets: ¹⁶ 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma Mechanism of Action: ¹⁹ Target: human cells Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production) FDA: ProleukinÂ® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
4	Sutent ¹⁹ ⁵⁰	SUNITINIB MALATE	Pfizer	May 2011/ January 2006
FDA Label: Sutent Disease/s that Drug Treats:pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors Indications and Usage: ¹⁹ SUTENT is a kinase inhibitor indicated for the treatment of: Gastrointestinal stromal tumor (GIST) after disease progression on orintolerance to imatinib mesylate. (1.1) Advanced renal cell carcinoma (RCC). (1.2) Progressive, well-differentiated pancreatic neuroendocrine tumors(pNET) in patients with unresectable locally advanced or metastaticdisease. (1.3) DrugBank Targets: ¹⁶ 1. Platelet-derived growth factor receptor beta;2. Vascular endothelial growth factor receptor 1;3. Mast/stem cell growth factor receptor Kit;4. Vascular endothelial growth factor receptor 2;5. Vascular endothelial growth factor receptor 3;6. Receptor-type tyrosine-protein kinase FLT3;7. Macrophage colony-stimulating factor 1 receptor;8. Platelet-derived growth factor receptor alpha Mechanism of Action: ¹⁹ Target: variety of kinases, platelet-derived growth factor receptors (PDGFRÎ± and PDGFRÎ²), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET) Action: inhibitor FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which areimplicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib wasevaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitorof platelet-derived growth factor receptors (PDGFRÎ± and PDGFRÎ²), vascular endothelial growth factorreceptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3(FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factorreceptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical andcellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primarymetabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRï¢, VEGFR2, KIT) in tumor xenograftsexpressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/orinhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibitgrowth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibitPDGFRï¢- and VEGFR2-dependent tumor angiogenesis in vivo.
5	Torisel ¹⁹ ⁵⁰	TEMSIROLIMUS	Wyeth	May 2007
FDA Label: Torisel Disease/s that Drug Treats:renal cell carcinoma Indications and Usage: ¹⁹ TORISELÂ® is a kinase inhibitor indicated for the treatment of advanced renalcell carcinoma. (1) DrugBank Targets: ¹⁶ 1. Serine/threonine-protein kinase mTOR Mechanism of Action: ¹⁹ Target: mTOR Action: inhibitor FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds toan intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTORthat controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treatedtumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomalprotein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. Inin vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTORand resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and thevascular endothelial growth factor.

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 632)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Sirolimus

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

53123-88-9

46835353 5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

22916-47-8

4189

Everolimus

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

159351-69-6

70789204 6442177

Bevacizumab

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

216974-75-3

Aldesleukin

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

110942-02-4, 85898-30-2

Sunitinib

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

557795-19-4, 341031-54-7

5329102

nivolumab

Approved

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

946414-94-4

Ipilimumab

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

477202-00-9

Dactinomycin

Approved, Investigational

Phase 4,Phase 3,Phase 2

50-76-0

457193 2019

Doxorubicin

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

23214-92-8

31703

Vincristine

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1

2068-78-2, 57-22-7

5978

Cyclophosphamide

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

50-18-0, 6055-19-2

2907

Sorafenib

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

284461-73-0

216239 406563

Gemcitabine

Approved

Phase 4,Phase 3,Phase 2,Phase 1

95058-81-4

60750

Epinephrine

Approved, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

51-43-4

5816

Bupivacaine

Approved, Investigational

Phase 4,Phase 2,Phase 3

38396-39-3, 2180-92-9

2474

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4,Phase 2,Phase 3,Not Applicable

437-38-7

3345

Racepinephrine

Approved

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

329-65-7

838

Zoledronic Acid

Approved

Phase 4,Phase 3,Phase 1,Phase 2

118072-93-8

68740

Dexmedetomidine

Approved, Vet_approved

Phase 4

113775-47-6

5311068 68602

Midazolam

Approved, Illicit

Phase 4,Phase 1

59467-70-8

4192

Caffeine

Approved

Phase 4,Phase 1

58-08-2

2519

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Bupropion

Approved

Phase 4,Phase 2

34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4,Phase 2,Not Applicable

62-31-7, 51-61-6

681

Nicotine

Approved

Phase 4,Not Applicable

54-11-5

89594 942

Itraconazole

Approved, Investigational

Phase 4,Phase 3,Not Applicable

84625-61-6

55283

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4,Phase 1,Phase 2

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4,Phase 1,Phase 2

1177-87-3

Acetaminophen

Approved

Phase 4,Phase 2,Not Applicable

103-90-2

1983

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Ropivacaine

Approved

Phase 4

84057-95-4

175805 71273

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Epirubicin

Approved

Phase 4,Phase 1,Phase 2

56420-45-2

41867

Oxytetracycline

Approved, Investigational, Vet_approved

Phase 4

79-57-2

54715139 5280972

Doxil

Approved June 1999

Phase 4,Phase 3,Phase 2,Phase 1

31703

Pirarubicin

Investigational

Phase 4

72496-41-4

Anti-Infective Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Anti-Bacterial Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antifungal Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1

Antibiotics, Antitubercular

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Angiogenesis Modulating Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Angiogenesis Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1

Antineoplastic Agents, Immunological

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

interferons

Phase 4,Phase 3,Phase 2,Phase 1

Analgesics

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1913)

#	Name	Status	NCT ID	Phase	Drugs
1	A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.	Unknown status	NCT01206764	Phase 4	RAD001
2	The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy	Unknown status	NCT01413607	Phase 4
3	Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors	Unknown status	NCT00777504	Phase 4	usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
4	Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment	Completed	NCT02056587	Phase 4	Everolimus
5	Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method	Completed	NCT02988219	Phase 4	Bupivacaine-fentanyl
6	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00006864	Phase 4
7	Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib	Completed	NCT01514448	Phase 4	Everolimus (RAD001)
8	Effect of Zoledronic Acid in Patients With Renal Cell Cancer and Bone Metastasis	Completed	NCT00172003	Phase 4	Zoledronic acid
9	First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma	Completed	NCT01521715	Phase 4	Pazopanib
10	Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma	Completed	NCT00706706	Phase 4	Sunitinib Malate (SU011248)
11	Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)	Completed	NCT01266837	Phase 4	Everolimus
12	Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours	Completed	NCT02016391	Phase 4	Dexmedetomidine
13	Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy	Completed	NCT03323021	Phase 4
14	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients	Completed	NCT01402089	Phase 4	Sunitinib;Erlotinib;Midazolam;Caffeine
15	Doxycycline In Lymphangioleiomyomatosis (LAM)	Completed	NCT00989742	Phase 4	Doxycycline;Placebo
16	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking	Completed	NCT00666978	Phase 4	bupropion hydrochloride
17	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
18	Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation	Completed	NCT00336531	Phase 4	itraconazole
19	Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma	Recruiting	NCT02399124	Phase 4
20	Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery	Recruiting	NCT03824808	Phase 4	Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
21	Study of Nivolumab for Advanced Cancers in India	Recruiting	NCT03444766	Phase 4	Nivolumab
22	QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery	Recruiting	NCT03339284	Phase 4	Dexamethasone sodium phosphate;Ropivacaine Hydrocloride;Sodium Chloride 9mg/mL
23	Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot Assisted Partiel Nephrectomy	Recruiting	NCT03571490	Phase 4	Ropivacaine;Saline
24	Efficacy of IV Acetaminophen Versus Oral Acetaminophen	Recruiting	NCT03365622	Phase 4	acetaminophen;Acetaminophen;Placebos;Placebo Oral Tablet
25	Effects of a Neuroscience-based Technique on Post-traumatic Stress Disorder Symptoms, Inflammation, and Survival in Cancer Patients Announced of a Palliative Disease Progression and Their Partners	Recruiting	NCT03652298	Phase 4
26	An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma	Active, not recruiting	NCT02596035	Phase 4	Nivolumab
27	Effects of Anesthesia on Immunity in Cancer	Active, not recruiting	NCT03514550	Phase 4	Propofol;Sevoflurane
28	Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy	Active, not recruiting	NCT02570789	Phase 4	patients with sunitinib or pazopanib
29	Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma	Active, not recruiting	NCT02555748	Phase 4	Pazopanib;Sunitinib
30	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer	Active, not recruiting	NCT02982954	Phase 4	Nivolumab;Ipilimumab
31	Combination Therapy of Anthracyclines for Children With Nephroblastoma	Not yet recruiting	NCT03892330	Phase 4	Vincristine;Oxytetracycline/ Cyclophosphamide;Liposomal doxorubicin;Doxorubicin;Pharmorubicin;Pirarubicin
32	Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)	Terminated	NCT02338570	Phase 4	Everolimus
33	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma	Terminated	NCT00930345	Phase 4	Sunitinib (SUTENT)
34	Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib	Terminated	NCT00352859	Phase 4	Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
35	Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy	Terminated	NCT01486550	Phase 4	Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
36	Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer	Unknown status	NCT01099423	Phase 3
37	Exercise for Patients With Renal Cell Cancer Receiving Sunitinib	Unknown status	NCT00869011	Phase 3
38	Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma	Unknown status	NCT01481870	Phase 3	Sorafenib-sunitinib;Sunitinib-sorafenib
39	Chemotherapy Plus Surgery in Treating Children at Risk of or With Stage I Wilms' Tumor	Unknown status	NCT00003804	Phase 3	vincristine sulfate
40	Chemotherapy Before and After Surgery in Treating Children With Wilm's Tumor	Unknown status	NCT00047138	Phase 3	carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
41	Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium	Unknown status	NCT02928692	Phase 3	Minocycline;Placebo
42	Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex	Unknown status	NCT01730209	Phase 2, Phase 3	Everolimus;Placebo
43	Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer	Unknown status	NCT01987596	Phase 3
44	Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00416429	Phase 3	medroxyprogesterone
45	Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00416871	Phase 3
46	AE-941 in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00005995	Phase 3	shark cartilage extract AE-941
47	Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00002737	Phase 3	chemotherapy;isotretinoin
48	Interleukin-2 in Treating Patients With Metastatic Kidney Cancer	Completed	NCT00018941	Phase 3
49	Kidney-Sparing Surgery Compared With Kidney Removal in Treating Patients With Kidney Cancer	Completed	NCT00002473	Phase 3
50	Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer	Completed	NCT00005966	Phase 3	thalidomide

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :

aldesleukin

axitinib

cabozantinib

hydroxyurea

interferon alfa-2a

interferon alfa-2b

interferon alfa-3n,human leukocyte derived

interferon alfacon-1

interferon gamma-1b

interferons

lenvatinib

lomustine

medroxyprogesterone

medroxyprogesterone acetate

peginterferon alfa-2a

peginterferon alfa-2b

recombinant interferon beta-1a

recombinant interferon beta-1b

sorafenib

sunitinib

sunitinib malate

temsirolimus

thalidomide

vinblastine

vinblastine sulfate

Cochrane evidence based reviews: kidney neoplasms

Sources

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

#	Genetic test	Affiliating Genes
1	Renal Cancer ³⁰

Sources

Anatomical Context for Kidney Cancer

MalaCards organs/tissues related to Kidney Cancer:

⁴²

Kidney, Lung, Bone, Endothelial, Prostate, Brain, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

²⁰

The Kidney

Sources

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 2741)

#	Title	Authors	Year
1	A human case of Dioctophyma renale (giant kidney worm) accompanied by renal cancer and a retrospective study of dioctophymiasis. ( 30963996 )	Yang F...Ling H	2019
2	Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer. ( 31039771 )	Vasileiadis T...Sdrolia A	2019
3	Lessons Learned from the Global Epidemiology of Kidney Cancer: A Refresher in Epidemiology 101. ( 30274700 )	Klaassen Z...Wallis CJD	2019
4	Increasing kidney cancer incidence and survival in Estonia: role of age and stage. ( 30280624 )	Innos K...Aareleid T	2019
5	Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. ( 30293904 )	Fu Q...Xu J	2019
6	Occupation and Risk of Kidney Cancer in Nordic Countries. ( 30308621 )	Michalek IM...Pukkala E	2019
7	Impact of Perioperative Blood Transfusions on the Outcomes of Patients Undergoing Kidney Cancer Surgery: A Systematic Review and Pooled Analysis. ( 30341027 )	Arcaniolo D...Autorino R	2019
8	Radiomics in Kidney Cancer: MR Imaging. ( 30466904 )	de Leon AD...Pedrosa I	2019
9	Improved Survival Outcomes for Kidney Cancer Patients With Brain Metastases. ( 30538068 )	Bowman IA...Brugarolas J	2019
10	Combination therapy for advanced and metastatic kidney cancer. ( 30538301 )	Lee CH...Motzer RJ	2019
11	Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. ( 30663998 )	Nayan M...Hamilton RJ	2019
12	Systematic review of modifiable risk factors for kidney cancer. ( 30685335 )	Al-Bayati O...Liss MA	2019
13	Surgical treatment of liver metastases from kidney cancer: a systematic review. ( 30685878 )	Pinotti E...Romano F	2019
14	Case-control investigation of occupational lead exposure and kidney cancer. ( 30760604 )	Callahan CL...Purdue MP	2019
15	Kidney cancer incidence rates in the world from the Cancer Incidence in Five Continents XI. ( 30789667 )	Hori M...Matsuoka J	2019
16	Correction to: SEOM clinical guideline for treatment of kidney cancer (2017). ( 30798511 )	Gallardo E...Su?rez C	2019
17	Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. ( 30817292 )	Kapoor A...Wong NC	2019
18	Examining Public Communication About Kidney Cancer on Twitter. ( 30860867 )	Sedrak MS...Bergerot PG	2019
19	Heavy metals, welding fumes, and other occupational exposures, and the risk of kidney cancer: A population-based nested case-control study in three Nordic countries. ( 30903816 )	Michalek IM...Pukkala E	2019
20	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. ( 30914797 )	Porta C...Bex A	2019
21	Inhibition of kidney cancer cell growth by Mulberroside-A is mediated via mitochondrial mediated apoptosis, inhibition of cell migration and invasion and targeting EGFR signalling pathway. ( 30941984 )	Duan C...Lin Y	2019
22	Demographic, medical, social-cognitive, and environmental correlates of meeting independent and combined physical activity guidelines in kidney cancer survivors. ( 30980259 )	Tabaczynski A...Trinh L	2019
23	Chlorogenic acid inhibits proliferation and induces apoptosis in A498 human kidney cancer cells via inactivating PI3K/Akt/mTOR signalling pathway. ( 30989669 )	Wang X...Yin Z	2019
24	Immune-based combination therapy for metastatic kidney cancer. ( 30992548 )	Porta C...Rizzo M	2019
25	Association Between Hospitals' Risk-Adjusted Emergency Department Visits and Survival and Costs in Kidney Cancer Patients Undergoing Nephrectomy. ( 31000485 )	Segel JE...Hollenbeak CS	2019
26	CD18 inhibits progression of kidney cancer by down-regulating Treg cell levels. ( 31002125 )	Fu JH...Lu DQ	2019
27	Kidney Cancer and Surgical Metastasectomy: Effective Therapy or Part of Disease Natural History? ( 31017090 )	Russo P	2019
28	Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system. ( 31032312 )	Patel HV...Singer EA	2019
29	Predicting renal function after kidney cancer surgery: a tool for clinical decision making. ( 31032324 )	Swavley NR...Autorino R	2019
30	Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. ( 31063051 )	Huang WC...Campbell SC	2019
31	Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now? ( 31082942 )	Kokorovic A...Rendon RA	2019
32	Inherited kidney cancer syndromes. ( 31083011 )	Ball MW...Shuch BM	2019
33	The Metabolic Basis of Kidney Cancer. ( 31088840 )	Linehan WM...Ricketts CJ	2019
34	Improving the Timely Detection of Bladder and Kidney Cancer in Primary Care. ( 31102201 )	Zhou Y...Walter FM	2019
35	Obstacles in Renal Regenerative Medicine: Metabolic and Epigenetic Parallels Between Cellular Reprogramming and Kidney Cancer Oncogenesis. ( 28847686 )	Lichner Z...Yousef GM	2019
36	Post-operative complications increase the risk of long-term chronic kidney disease after nephron sparing surgery in renal cancer patients with normal preoperative renal function. ( 30768877 )	Ventimiglia E...Capitanio U	2019
37	Renal Cancer Surgery in Patients without Preexisting Chronic Kidney Disease: Is There a Survival Benefit for Partial Nephrectomy? ( 30694940 )	Suk-Ouichai C...Campbell SC	2019
38	Prolonged survival of renal cancer patients is concomitant with a higher regucalcin gene expression in tumor tissues: Overexpression of regucalcin suppresses the growth of human renal cell carcinoma cells in vitro. ( 30387835 )	Yamaguchi M...Murata T	2019
39	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. ( 30125350 )	Saeed K...?stling P	2019
40	Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase. ( 30658233 )	Ibrahim HS...Abdel-Aziz HA	2019
41	Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. ( 30675211 )	Qiu J...Ding K	2019
42	Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. ( 30680522 )	K?stek O...Erdo?an B	2019
43	Interactive virtual 3D models of renal cancer patient anatomies alter partial nephrectomy surgical planning decisions and increase surgeon confidence compared to volume-rendered images. ( 30680601 )	Hyde ER...Mumtaz FH	2019
44	3D reconstruction of CT scans aid in preoperative planning for sarcomatoid renal cancer: A case report and mini-review. ( 30689600 )	Glybochko PV...Butnaru DV	2019
45	The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. ( 30704958 )	Capogrosso P...Capitanio U	2019
46	High expression of TAZ serves as a novel prognostic biomarker and drives cancer progression in renal cancer. ( 30731073 )	Ruan H...Zhang X	2019
47	Specific immune cell and lymphatic vessel signatures identified by image analysis in renal cancer. ( 30737470 )	Schraml P...Moch H	2019
48	Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2. ( 30745848 )	Liu M...Jin C	2019
49	PET imaging in renal cancer. ( 30747736 )	Lindenberg L...Bouchelouche K	2019
50	Re: Time Trends in Service Provision and Survival Outcomes for Patients with Renal Cancer Treated by Nephrectomy in England 2000-2010. ( 30747866 )	Laguna MP	2019

Sources

Genes for Kidney Cancer

Genes related to Kidney Cancer (2 elite genes):

(show top 50) (show all 53)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	MTOR	Mechanistic Target Of Rapamycin Kinase	Protein Coding	431.84	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	20364382 19165638
2	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	429.17	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	19496715 15579033 10874308 (more) 10491015 17255292 19318488
3	KCNQ1OT1	KCNQ1 Opposite Strand/Antisense Transcript 1	RNA Gene	154.38	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	24373479
4	PVT1	Pvt1 Oncogene	RNA Gene	153.99	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	27366943 17881614
5	GAS5	Growth Arrest Specific 5	RNA Gene	153.42	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	24373479
6	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	153.33	Experimental evidence ⁴⁰ DISEASES inferred ¹⁵	25149152 24616104
7	HIF1A-AS2	HIF1A Antisense RNA 2	RNA Gene	153.2	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	24373479 9923855
8	EPB41L4A-DT	EPB41L4A Divergent Transcript	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	26980733
9	RNY3	RNA, Ro60-Associated Y3	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	18283318
10	RNY1	RNA, Ro60-Associated Y1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	18283318
11	MEG3	Maternally Expressed 3	RNA Gene	150	Experimental evidence: Expression ⁴⁰	24373479
12	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	26461224 26254614 24373479
13	HIF1A-AS1	HIF1A Antisense RNA 1	RNA Gene	150	Experimental evidence: Expression ⁴⁰	24373479 21897117 9923855
14	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	150	Experimental evidence: Expression ⁴⁰	24373479
15	MIR21	MicroRNA 21	RNA Gene	56.02	Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	19646430
16	MIR17	MicroRNA 17	RNA Gene	56.02	Unspecified ⁴⁸ GeneCards inferred via : Publications (show sections)	19646430
17	MIR150	MicroRNA 150	RNA Gene	50	Unspecified ⁴⁸	19646430
18	MIR15A	MicroRNA 15a	RNA Gene	50	Unspecified ⁴⁸	19646430
19	MIR191	MicroRNA 191	RNA Gene	50	Unspecified ⁴⁸	19646430
20	MIR200B	MicroRNA 200b	RNA Gene	50	Unspecified ⁴⁸	19646430
21	MIR200C	MicroRNA 200c	RNA Gene	50	Unspecified ⁴⁸ ⁴⁸	19646430 18925646
22	MIR141	MicroRNA 141	RNA Gene	50	Unspecified ⁴⁸	18925646
23	MIR29C	MicroRNA 29c	RNA Gene	50	Unspecified ⁴⁸	19646430
24	MIR340	MicroRNA 340	RNA Gene	50	Unspecified ⁴⁸	19646430
25	MIR106A	MicroRNA 106a	RNA Gene	50	Unspecified ⁴⁸	19646430
26	MIRLET7F2	MicroRNA Let-7f-2	RNA Gene	50	Unspecified ⁴⁸	17826655
27	MIR106B	MicroRNA 106b	RNA Gene	50	Unspecified ⁴⁸	19646430
28	MIR28	MicroRNA 28	RNA Gene	50	Unspecified ⁴⁸	17826655
29	MIR182	MicroRNA 182	RNA Gene	50	Unspecified ⁴⁸	19646430
30	MIR20A	MicroRNA 20a	RNA Gene	50	Unspecified ⁴⁸	19646430
31	MIR20B	MicroRNA 20b	RNA Gene	50	Unspecified ⁴⁸	19646430
32	MIR210	MicroRNA 210	RNA Gene	50	Unspecified ⁴⁸	19646430
33	MIR214	MicroRNA 214	RNA Gene	50	Unspecified ⁴⁸	19646430
34	MIR27A	MicroRNA 27a	RNA Gene	50	Unspecified ⁴⁸	19646430
35	MIR378A	MicroRNA 378a	RNA Gene	50	Unspecified ⁴⁸	19646430
36	MIR424	MicroRNA 424	RNA Gene	50	Unspecified ⁴⁸	19646430
37	MIR489	MicroRNA 489	RNA Gene	50	Unspecified ⁴⁸	19646430
38	MIR122	MicroRNA 122	RNA Gene	50	Unspecified ⁴⁸	19646430
39	MIR126	MicroRNA 126	RNA Gene	50	Unspecified ⁴⁸	19646430
40	MIR7-2	MicroRNA 7-2	RNA Gene	50	Unspecified ⁴⁸	17826655
41	MIR185	MicroRNA 185	RNA Gene	50	Unspecified ⁴⁸	17826655
42	MIR29A	MicroRNA 29a	RNA Gene	50	Unspecified ⁴⁸	19646430
43	VHL	Von Hippel-Lindau Tumor Suppressor	Protein Coding	44.65	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications Summaries (show sections)	12169691 18389622 9820032 (more) 15180922 18676741 19052740 20054297 10878820 12019174 12907635 17382186 18245539 18806787 10766184 16585181 19620968 10971171 11406557 20059341 15251937 19402075 8741802 17220275 17526729 17255292 19061830 15177666 18039096 20448661 10421634 10454237 12538644 12853837
44	IL2	Interleukin 2	Protein Coding	35.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	2253233 9166506 1567700 (more) 7960603 15285881 9742914 8249176 10768598 15897568 15869448 9474133 18794104 9376197 14503947 17571248 12806282 8023699 18298334 16686731 8355047 19452104 15102596 2386896 1931865 8435431 7537108 8540123 8928360 15448028 1742732 19801515 19663736 18836339 17545537 17105418 17069529 16531726 15667466 9815721 8567975 7935991 8508201 1830670 2142395 7521786 19409039 18528297 9703284 9192992 8547958 7539867 8286206 1464035 1423266 2149997 19675744 1416748 1627272 1991296 2093734 2289209 19639177 15994271 10840936 19663247 16351658 16113605 12803881 11118461 10996626 10999727 18031135 17105423 11357146 9238157 9604779 1746923 1954382 1832885 17932908 15778577 11033521 8204946 1609217 1803863 1868045 2337757 2036660 18928373 16514482 17728709 14760375 11129083 9671141 8236501 14650831 8615668 7610516 7804369
45	FH	Fumarate Hydratase	Protein Coding	34.96	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16029320 16098467 18986479 (more) 17270241 19470762 14708972 15579034 16364563 17211469 12761039 15924063 15937070 20091131 14643060 16597677
46	FLCN	Folliculin	Protein Coding	33.27	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15657874 18234728 19418834 (more) 16825879 18182616 12204536 15143337
47	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	32.47	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	19110567 19891126 19138891 (more) 17362927 10216508 19238017 20080466 18566209 19948455 15610695 19365880 19402056 18673245 17470689 16429647 15780170 15235386 19165638 18039096 20425594 20033382 17044086 17949520 9815646 19531449 12890838 19451442 15314526
48	TP53	Tumor Protein P53	Protein Coding	31.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Variants (show sections)
49	KDR	Kinase Insert Domain Receptor	Protein Coding	28.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	16824050 19110567
50	FHIT	Fragile Histidine Triad Diadenosine Triphosphatase	Protein Coding	28.14	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁶ GeneCards inferred via : Publications (show sections)	15080505 9290948 9391102 (more) 11712940 9679951 11320209 15357873 9403704 11406557

Sources

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

⁶ (show all 18)

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	MET	NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913246	GRCh37	Chromosome 7, 116423414: 116423414
2	MET	NM_001127500.2(MET): c.3743A> G (p.Tyr1248Cys)	single nucleotide variant	Pathogenic/Likely pathogenic	rs121913246	GRCh38	Chromosome 7, 116783360: 116783360
3	MET	NM_001127500.1(MET): c.3335A> G (p.His1112Arg)	single nucleotide variant	Pathogenic	rs121913243	GRCh37	Chromosome 7, 116417464: 116417464
4	MET	NM_001127500.1(MET): c.3335A> G (p.His1112Arg)	single nucleotide variant	Pathogenic	rs121913243	GRCh38	Chromosome 7, 116777410: 116777410
5	MET	NM_001127500.2(MET): c.3742T> C (p.Tyr1248His)	single nucleotide variant	Uncertain significance	rs121913247	GRCh37	Chromosome 7, 116423413: 116423413
6	MET	NM_001127500.2(MET): c.3742T> C (p.Tyr1248His)	single nucleotide variant	Uncertain significance	rs121913247	GRCh38	Chromosome 7, 116783359: 116783359
7	MET	NM_001127500.2(MET): c.3334C> T (p.His1112Tyr)	single nucleotide variant	Likely pathogenic	rs121913244	GRCh37	Chromosome 7, 116417463: 116417463
8	MET	NM_001127500.2(MET): c.3334C> T (p.His1112Tyr)	single nucleotide variant	Likely pathogenic	rs121913244	GRCh38	Chromosome 7, 116777409: 116777409
9	MET	NM_001127500.2(MET): c.3803T> C (p.Met1268Thr)	single nucleotide variant	Likely pathogenic	rs121913245	GRCh37	Chromosome 7, 116423474: 116423474
10	MET	NM_001127500.2(MET): c.3803T> C (p.Met1268Thr)	single nucleotide variant	Likely pathogenic	rs121913245	GRCh38	Chromosome 7, 116783420: 116783420
11	MTOR	NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro)	single nucleotide variant	Likely pathogenic	rs1057519777	GRCh37	Chromosome 1, 11169361: 11169361
12	MTOR	NM_004958.3(MTOR): c.7514G> C (p.Arg2505Pro)	single nucleotide variant	Likely pathogenic	rs1057519777	GRCh38	Chromosome 1, 11109304: 11109304
13	MTOR	NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys)	single nucleotide variant	Likely pathogenic	rs1057519778	GRCh37	Chromosome 1, 11182179: 11182179
14	MTOR	NM_004958.3(MTOR): c.6667C> A (p.Gln2223Lys)	single nucleotide variant	Likely pathogenic	rs1057519778	GRCh38	Chromosome 1, 11122122: 11122122
15	MTOR	NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs587777894	GRCh37	Chromosome 1, 11184573: 11184573
16	MTOR	NM_004958.3(MTOR): c.6644C> A (p.Ser2215Tyr)	single nucleotide variant	Pathogenic/Likely pathogenic	rs587777894	GRCh38	Chromosome 1, 11124516: 11124516
17	MTOR	NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519779	GRCh37	Chromosome 1, 11217299: 11217299
18	MTOR	NM_004958.3(MTOR): c.4379T> C (p.Leu1460Pro)	single nucleotide variant	Pathogenic/Likely pathogenic	rs1057519779	GRCh38	Chromosome 1, 11157242: 11157242

Cosmic variations for Kidney Cancer:

⁹ (show top 50) (show all 260)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location
1	COSM6941466	XIAP	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.563G>C	p.G188A	23:123886225-123886225
2	COSM14312	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.353T>C	p.L118P	3:10146526-10146526
3	COSM14380	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.548C>A	p.S183*	3:10149871-10149871
4	COSM18350	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.256C>T	p.P86S	3:10142103-10142103
5	COSM17957	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.292T>G	p.Y98D	3:10142139-10142139
6	COSM14305	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.266T>A	p.L89H	3:10142113-10142113
7	COSM14382	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.245G>C	p.R82P	3:10142092-10142092
8	COSM25676	VHL	kidney,NS,carcinoma,renal cell	c.485G>T	p.C162F	3:10149808-10149808
9	COSM17875	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.234T>G	p.N78K	3:10142081-10142081
10	COSM17983	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.500G>A	p.R167Q	3:10149823-10149823
11	COSM18097	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.482G>A	p.R161Q	3:10149805-10149805
12	COSM14425	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.341-2A>T	p.?	3:10146512-10146512
13	COSM17872	VHL	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.217C>T	p.Q73*	3:10142064-10142064
14	COSM27269	UMPS	kidney,NS,carcinoma,renal cell	c.528G>A	p.L176L	3:124737785-124737785
15	COSM7349320	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1119+1G>T	p.?	16:2060814-2060814
16	COSM7349613	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.976-1G>A	p.?	16:2060669-2060669
17	COSM7349594	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.2356-1G>C	p.?	16:2074199-2074199
18	COSM7349602	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1636G>T	p.E546*	16:2065555-2065555
19	COSM7349619	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.390C>G	p.Y130*	16:2054349-2054349
20	COSM7349321	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1600-1G>T	p.?	16:2065518-2065518
21	COSM7349621	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.774+1G>A	p.?	16:2056770-2056770
22	COSM7349639	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.731G>T	p.C244F	16:2056726-2056726
23	COSM7349636	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1189C>T	p.Q397*	16:2061940-2061940
24	COSM6957851	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.541G>A	p.V181M	16:2055461-2055461
25	COSM7349616	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1717-1G>C	p.?	16:2070455-2070455
26	COSM1272079	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.3412C>T	p.R1138*	16:2080179-2080179
27	COSM6943738	TSC2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.975+1G>T	p.?	16:2058874-2058874
28	COSM7349328	TSC1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1835T>A	p.L612*	9:132905743-132905743
29	COSM7349331	TSC1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1276G>T	p.D426Y	9:132907358-132907358
30	COSM6942356	TSC1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.2287C>T	p.Q763*	9:132902709-132902709
31	COSM6963117	TSC1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1001C>A	p.S334*	9:132911481-132911481
32	COSM29770	TSC1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.508+1G>T	p.?	9:132923347-132923347
33	COSM30474	TRIO	kidney,NS,carcinoma,renal cell	c.9008A>G	p.N3003S	5:14508136-14508136
34	COSM10656	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.742C>T	p.R248W	17:7674221-7674221
35	COSM45243	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.374C>G	p.T125R	17:7675995-7675995
36	COSM44310	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.738G>A	p.M246I	17:7674225-7674225
37	COSM6922197	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.97-2A>C	p.?	17:7676274-7676274
38	COSM45135	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.673-1G>T	p.?	17:7674291-7674291
39	COSM10647	TP53	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.404G>T	p.C135F	17:7675208-7675208
40	COSM6929752	TBX3	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.510G>T	p.W170C	12:114681026-114681026
41	COSM6979493	STAG2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.2096+1G>A	p.?	23:124065947-124065947
42	COSM6975582	STAG2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1348A>T	p.R450*	23:124057909-124057909
43	COSM6023628	STAG2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.2860C>T	p.R954C	23:124081464-124081464
44	COSM6963119	SPOP	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.265T>G	p.L89V	17:49619321-49619321
45	COSM6964939	SMARCB1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.987-2A>T	p.?	22:23833570-23833570
46	COSM989	SMARCB1	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.1130G>A	p.R377H	22:23834152-23834152
47	COSM1266238	SMARCA4	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.3575G>A	p.R1192H	19:11033318-11033318
48	COSM6947611	SETD2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.863C>A	p.S288*	3:47122264-47122264
49	COSM6975580	SETD2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.4736C>G	p.S1579*	3:47062211-47062211
50	COSM4118007	SETD2	kidney,NS,carcinoma,renal cell carcinoma unclassified	c.3266G>A	p.R1089Q	3:47106061-47106061

Copy number variations for Kidney Cancer from CNVD:

⁷

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	166351	3	10158318	10168746	Mutations	VHL	Renal cancer

Sources

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Sources

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	MicroRNAs in cancer ³⁸	11.64	MET MIR150 MIR15A MIR17 MIR200B MIR21
2	LncRNA-mediated mechanisms of therapeutic resistance ¹	10.03	HOTAIR MEG3

Sources

GO Terms for Kidney Cancer

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	micro-ribonucleoprotein complex	GO:0035068	9.23	H19 MEG3 MIR150 MIR15A MIR17 MIR191

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular response to hypoxia	GO:0071456	9.65	MALAT1 MIR17 MTOR
2	negative regulation of angiogenesis	GO:0016525	9.63	MIR15A MIR200B MIR21
3	miRNA mediated inhibition of translation	GO:0035278	9.54	MIR15A MIR17 MIR21
4	chromatin silencing	GO:0006342	9.52	HOTAIR KCNQ1OT1
5	negative regulation of stress fiber assembly	GO:0051497	9.51	MET MIR21
6	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.49	MIR15A MIR21
7	positive regulation of endothelial cell differentiation	GO:0045603	9.43	MIR150 MIR21
8	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.4	MIR17 MIR21
9	regulation of protein kinase B signaling	GO:0051896	9.32	MIR21 MTOR
10	positive regulation of metalloendopeptidase activity	GO:1904685	9.26	MIR17 MIR21
11	gene silencing by miRNA	GO:0035195	9.23	H19 MEG3 MIR150 MIR15A MIR17 MIR191
12	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.16	MIR17 MIR21
13	negative regulation of hydrogen peroxide-mediated programmed cell death	GO:1901299	8.96	MET MIR21

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.1	MIR150 MIR15A MIR17 MIR191 MIR200B MIR21

Sources

Sources for Kidney Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia

Kidney Cancer

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Classifications:

External Ids:

Summaries for Kidney Cancer

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Kidney Cancer:

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:

Drugs & Therapeutics for Kidney Cancer

FDA approved drugs:

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Inferred drug relations via UMLS 74 / NDF-RT 52 :

Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Genetic tests related to Kidney Cancer:

Anatomical Context for Kidney Cancer

MalaCards organs/tissues related to Kidney Cancer:

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

Publications for Kidney Cancer

Articles related to Kidney Cancer:

Genes for Kidney Cancer

Genes related to Kidney Cancer (2 elite genes):

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

Cosmic variations for Kidney Cancer:

Copy number variations for Kidney Cancer from CNVD:

Expression for Kidney Cancer

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

GO Terms for Kidney Cancer

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

Sources for Kidney Cancer

Inferred drug relations via UMLS ⁷⁴ / NDF-RT ⁵² :